SCHEMBL719865

SCHEMBL719865

c1ccc(CCc2ccco2)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.46
MAPT P10636 2/20 0.46
RAB9A P51151 2/20 0.46
NPC1 O15118 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
ALDH1A1 P00352 7/20 0.45
DAO P14920 1/20 0.44
HPGD P15428 3/20 0.44
ALOX15 P16050 2/20 0.44
CYP3A4 P08684 1/20 0.44
USP2 O75604 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
GPR52 Q9Y2T5 1/20 0.43
MAOA P21397 2/20 0.43
MAOB P27338 2/20 0.43
ALOX12 P18054 1/20 0.42
CASP1 P29466 1/20 0.42
HSD17B10 Q99714 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
CA1 P00915 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7364038 0.87 ALDH1A1 (0.50) L3MBTL1MAPTRAB9ANPC1SMN1; SMN2
SCHEMBL8146532 0.85 ALDH1A1 (0.54) MAPTALDH1A1HPGDALOX15CYP3A4
SCHEMBL20324688 0.83 OPRM1 (0.40) L3MBTL1MAPTRAB9AALDH1A1HPGD
SCHEMBL510357 0.81 ALDH1A1 (0.41) L3MBTL1MAPTRAB9ASMN1; SMN2ALDH1A1
SCHEMBL21622784 0.81 ALDH1A1 (0.55) L3MBTL1MAPTALDH1A1HPGDALOX15
SCHEMBL1711865 0.81 ALDH1A1 (0.44) L3MBTL1MAPTRAB9ASMN1; SMN2ALDH1A1
SCHEMBL1255865 0.81 LOXL2 (0.43) RAB9ANPC1ALDH1A1HPGDALOX15
SCHEMBL21622787 0.81 RAB9A (0.44) MAPTRAB9ANPC1SMN1; SMN2ALDH1A1
SCHEMBL9376259 0.81 GFER (0.56) MAPTRAB9ANPC1SMN1; SMN2ALDH1A1
SCHEMBL596315 0.79 CALM1 (0.50) L3MBTL1MAPTALDH1A1USP2HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 138 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-4818110-B2 2011-11-16 JP claimed
EP-1948633-B1 3 -HYDROXYFLAVONE DERIVATIVES FOR THE DETECTION AND THE QUANTIFICATION OF CELL APOPTOSIS CENTRE NAT RECH SCIENT (FR) 2011-08-10 EP claimed
US-7880021-B2 reacting 6-bromomethyl-4'-(diethylamino)-3-hydroxyflavone with dodecylmethylamine to form the corresponding tertiary amine (4'-(diethylamino)-6-(dodecyl(methyl)aminomethyl)-3-hydroxyflavone); and reacting the product of step a. with propansultone; use in biomembrane studies; Alzheimer's disease, cancer CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 2011-02-01 US claimed
US-20090269793-A1 Compounds and Kits for the Detection and the Quantification of Cell Apoptosis Centre National De La Recherche Scientifiique (CNRS) 2009-10-29 US claimed
JP-2009511566-A 2009-03-19 JP claimed
EP-1218383-B1 BICYCLIC IMIDAZO-5-YL-AMINE DERIVATIVES GRUENENTHAL GMBH (DE) 2008-11-05 EP claimed
EP-1651621-B1 2- (QUINOXALIN-5-YLSULFONYLAMINO) -BENZAMIDE COMPOUNDS AS CCK2 MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2008-08-06 EP claimed
EP-1948633-A2 3 -HYDROXYFLAVONE DERIVATIVES FOR THE DETECTION AND THE QUANTIFICATION OF CELL APOPTOSIS CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 2008-07-30 EP claimed
US-7304051-B2 Quinoxaline compounds JANSSEN PHARMACEUTICA N.V. (BE) 2007-12-04 US claimed
US-7241759-B2 Benzo[1,2,5]thiadiazole compounds JANSSEN PHARMACEUTICA N.V. (BE) 2007-07-10 US claimed
US-20020183320-A1 Bicyclic imidazo-5-yl-amine derivatives GRUENENTHAL GMBH (DE) 2002-12-05 US claimed
EP-1218383-A2 BICYCLIC IMIDAZO-5-YL-AMINE DERIVATIVES Grünenthal GmbH (DE) 2002-07-03 EP claimed
EP-0754696-B1 Unsymmetric diphosphine monoxide compounds and a process for preparing diphosphine compounds TAKASAGO PERFUMERY CO LTD (JP) 2002-01-16 EP claimed
WO-2001081344-A1 SALTS OF BICYCLIC, N-ACYLATED IMIDAZO-3-AMINES AND IMIDAZO-5-AMINES Grünenthal GmbH (DE) 2001-11-01 WO claimed
WO-2001027119-A2 SUBSTANCE LIBRARY CONTAINING BICYCLIC IMIDAZO-5-YL-AMINES AND/OR BICYCLIC IMIDAZO-3-YL-AMINES Grünenthal GmbH (DE) 2001-04-19 WO claimed
WO-2001027118-A2 BICYCLIC IMIDAZO-5-YL-AMINE DERIVATIVES Grünenthal GmbH (DE) 2001-04-19 WO claimed
US-6117887-A ANTIPROLIFERATIVE AGENTS CV THERAPEUTICS, INC. (US) 2000-09-12 US claimed
US-5808162-A Chiral unsymmetric diphosphine compound and transition metal complex containing the same as ligand TAKASAGO INTERNATIONAL CORPORATION (JP) 1998-09-15 US claimed
EP-0754696-A1 Chiral unsymmetric diphosphine compounds and transition metal complexes containing them as ligands Takasago International Corporation (JP) 1997-01-22 EP claimed
US-4558038-A HYPOTENSIVE AGENTS USV PHARMACEUTICAL CORP. (US) 1985-12-10 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020183320-A1 Bicyclic imidazo-5-yl-amine derivatives ACHE, P2RX5, CNR1 L3MBTL1 4711/4885MAPT 3783/4885RAB9A 3617/4885
US-20090269793-A1 Compounds and Kits for the Detection and the Quantification of Cell Apoptosis BAX, CASP3, BCL2 L3MBTL1 489/4885MAPT 4847/4885RAB9A 2451/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.